{"id":"guaiapate","rwe":[{"pmid":"367681","year":"1978","title":"[Clinical evaluation of a synthetic cough sedative: guaiapate].","finding":"","journal":"La Clinica terapeutica","studyType":"Clinical Study"}],"tags":[{"label":"guaiapate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"klamar","offLabel":[],"synonyms":["guaiapate","klamar"],"timeline":[],"approvals":[],"brandName":"Klamar","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"guaiapate","explanation":"Imagine your body's cells are like locks, and Klamar is a key that fits into one of those locks. When it binds to the lock, it triggers a response that helps to treat a particular condition. This is a simplified explanation of how Klamar might work, but the actual mechanism is likely more complex and involves specific biochemical interactions.","oneSentence":"Klamar (GUAIAPATE) is thought to work by interacting with a specific biological target to produce a therapeutic effect.","technicalDetail":"The technical details of Klamar's mechanism of action are not available, but it is likely to involve binding to a specific receptor or enzyme, triggering a downstream signaling cascade that produces a therapeutic effect."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3453","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GUAIAPATE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:49:09.064378","biosimilars":[],"competitors":[],"genericName":"guaiapate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"BDL7R8N38D","CHEBI":"CHEBI:135375","INN_ID":"2134","UMLSCUI":"C0601166","ChEMBL_ID":"CHEMBL2106641","KEGG_DRUG":"D04373","PUBCHEM_CID":"70066","MESH_SUPPLEMENTAL_RECORD_UI":"C001741"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"1978 Aug 31","pmid":"367681","title":"[Clinical evaluation of a synthetic cough sedative: guaiapate].","journal":"La Clinica terapeutica"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Klamar (GUAIAPATE) is a small molecule drug in the guaiapate class, but information on its target and mechanism of action is not available. Its commercial status and approved indications are also unknown. As a guaiapate, it is likely used to treat respiratory or gastrointestinal issues, but further research is needed to confirm its clinical applications. Klamar's safety profile, pharmacokinetics, and patent status are also unclear. Further investigation is required to fully understand this compound.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}